Fight CRC Clinical Trial Finder
| NCT ID | Title | Phase | Date Added | Location | Prior IO Allowed | CRC-directed | Status | Drugs | Tags |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT05333809 |
TitlePembrolizumab and Disitamab Vedotin in HER2-expressing Metastatic Colorectal Cancer | Phase
Phase 2
|
Date Added 2022-04-19 |
Location |
Prior IO Allowed No |
CRC-directed Yes |
Status
Not yet recruiting
|
Drugs
Disitamab vedotin, Pembrolizumab, Keytruda |
Tags
MSS/ MMRp
|
| NCT ID NCT05382442 |
TitleA Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer | Phase
Phase 2
|
Date Added 2022-05-19 |
Location
California, United States
China |
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
5-Fluorouracil, Bevacizumab, capecitabine, Irinotecan, Leucovorin, oxaliplatin |
Tags
MSS/ MMRp
|
| NCT ID NCT05480306 |
TitlePhase 2 Study of DKN-01 in Colorectal Cancer | Phase
Phase 2
|
Date Added 2022-07-29 |
Location
Arizona, United States
California, United States Florida, United States Louisiana, United States Maryland, United States Missouri, United States New York, United States North Carolina, United States South Carolina, United States South Dakota, United States Tennessee, United States Washington, United States Wisconsin, United States Germany Korea, Republic of |
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Bevacizumab, DKN-01, FOLFIRI, FOLFOX |
Tags
MSS/ MMRp
|
| NCT ID NCT05482516 |
TitleEvaluating Novel Therapies in ctDNA Positive GI Cancers | Phase
Phase 3
|
Date Added 2022-08-01 |
Location
District of Columbia, United States
New Jersey, United States |
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Atezolizumab, Bevacizumab, Avastin, Tecentriq |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05491083 |
TitlePembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer | Phase
Phase 1
|
Date Added 2022-08-08 |
Location |
Prior IO Allowed No |
CRC-directed No |
Status
Not yet recruiting
|
Drugs
Pembrolizumab & ADG106 (Phase Ib), Pembrolizumab & ADG106 (Phase II) |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT06300463 |
TitlePlatform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases | Phase
Phase 2
|
Date Added 2024-03-08 |
Location
New York, United States
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
AGEN1423, Balstilimab, Botensilimab |
Tags
MSS/ MMRp
|
| NCT ID NCT06336902 |
TitleBotensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorectal Cancer | Phase
Phase 1
|
Date Added 2024-03-29 |
Location
California, United States
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Balstilimab, Botensilimab |
Tags
MSS/ MMRp
|
| NCT ID NCT06152523 |
TitleMonalizumab and MEDI5752 in Patients With MSI and/or dMMR Metastatic Cancer | Phase
Phase 2
|
Date Added 2023-11-30 |
Location
France
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Not yet recruiting
|
Drugs
Monalizumab/MEDI5257 |
Tags
MSI-H/ MMRd
|
| NCT ID NCT04444622 |
TitleImmunotherapy for Third Line Metastatic Colorectal Cancer | Phase
Phase 2
|
Date Added 2020-06-23 |
Location
Florida, United States
Michigan, United States New Jersey, United States New York, United States |
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs |
Tags
MSS/ MMRp
|
| NCT ID NCT05879822 |
TitleA Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive | Phase
Phase 2
|
Date Added 2023-05-30 |
Location
Brazil
China Georgia Greece Hungary New Zealand Romania South Africa Turkey |
Prior IO Allowed No |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
INCB099280 |
Tags
MSI-H/ MMRd
|
